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1. Introduction 
Spinal cord injury (SCI) is one of the most complex and devastating medical conditions. Its 
worldwide incidence ranges from 11 to 112 per 100,000 Population (Blumer & Quine, 1995; 
DeVivo, 1997). SCI leads to different degrees of dysfunction of the lower urinary tract due to 
a large variety of possible lesions. Immediately after SCI, flaccid paralysis sets in, followed 
by the absence of reflexes and a complete loss of sensory and motor control below the level 
of lesion, rendering the urinary bladder areflexic and atonic. This period, termed spinal 
shock, can extend from a few days to several months (Chai & Steers, 1996). Most patients 
with suprasacral SCI suffer from detrusor over-activity (DO) and detrusor sphincter 
dyssynergia (DSD) (Blaivas et al., 1981). DSD leads to high intravesical pressure, high 
residual urine, urinary tract infection, and deterioration of the upper urinary tract. In order 
to recover the voluntary control of micturition, functional electrical stimulation (FES) has 
been investigated at different sites of the urinary system: the bladder muscle (detrusor), the 
pelvic nerves, the spinal cord and the sacral nerve roots. Among these, sacral nerve root 
stimulation is considered the most efficient technique to induce micturition and has been 
prevalent in clinical practice over the last two decades (Elabaddy et al., 1994). Using cuff-
electrodes, this technique offers the advantages of a safe and stable fixation of electrodes as 
well as confinement of the spread of stimulation current within the targeted nerves. 
However, the detrusor and the external urethral sphincter (EUS) muscles share the sacral 
nerves as common innervations pathways, and stimulation of the entire sacral root induces 
contraction of both. Thus, the efficiency of micturition by means of sacral neurostimulation 
depends on the capability to contract the detrusor without triggering EUS contraction. In 
order to improve this neurostimulation selectivity, several techniques have been proposed, 
among which are rhizotomy, and EUS blockade using high-frequency stimulation. 
Dorsal rhizotomy consists of selectively severing afferent sacral nerve roots that are 
involved in pathological reflex arc in suprasacral SCI patients. Rhizotomy abolishes DO, 
reduces DSD, and prevents autonomic dysreflexia. As a beneficial result, the uninhibited 
bladder contractions are reduced, the bladder capacity and compliance are increased, urine 
flow is improved, and consequently the upper urinary tract is protected from ureteral reflux 
and hydronephrosis. In case of a complete SCI, dorsal rhizotomy is combined with an 
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implantable sacral ventral root stimulator such as the Finetech-Brindley Bladder System 
(also known as the VOCARE in North America) (Kutzenberger, 2007). In fact, this 
neurostimulation system is the only commercialized and FDA-approved solution aiming for 
micturition in SCI patients (Jezernik et al., 2002). Unfortunately, rhizotomy being 
irreversible, it has a fundamental disadvantage which is the abolition of sexual and 
defecation reflexes, as well as sacral sensations if still present in case of incomplete SCI. 
High-frequency stimulation can be used to inhibit the contraction of the EUS muscle. 
However, the mechanism by which the EUS inhibition is obtained is not well understood 
and three explanations are possible: high-frequency stimulation may stop the propagation 
of nerve action potentials, may maintain the motor end-plate (neuromuscular junction) in a 
refractory status, or may fatigue the aimed muscle (Kilgore & Bhadra, 2004; Tai et al., 2005; 
Williamson & Andrews, 2005). Frequencies from 300 Hz to 30 kHz can be used to achieve a 
complete and reversible nerve conduction block depending on the stimulation amplitude 
(Solomonow, 1984; Sievert et al., 2002; Schuettler et al., 2004; Bhadra et al., 2006). However, 
below 1 kHz, a sinusoidal stimulation can generate action potentials at the same or a 
submultiple rate. Increasing the frequency has the advantage of lowering the amount of 
injected charge per-phase needed for a complete blockade. A graded blockade can also be 
achieved as blockade of each axon within the nerve is influenced by its diameter and the 
stimulation amplitude (Tai et al., 2005). If a graded blockade is applied distally in 
combination with low-frequency stimulation, selectivity with respect to axon diameter can 
be obtained by adjusting stimulation amplitude (Williamson & Andrews, 2005). Finally, 
combining sacral root stimulation with bilateral high-frequency pudendal nerve block led to 
effective micturition in male cats (Boger et al., 2008). 
The efficiency of high-frequency blockade was studied with dog experiments using a 
neurostimulator designed by Polystim Neurotechnologies Laboratory (Robin et al., 1998; 
Shaker et al., 1998; Ba et al., 2002; Sawan et al., 2008b). The Polystim’s stimulator generated a 
rectangular waveform combining two frequencies (e.g. 600 Hz and 30 Hz). It is important to 
point out in this case, that stimulation and blockade are both applied simultaneously at the 
same nerve site, with the same bipolar electrode. According to Kilgore et al. (Kilgore & 
Bhadra, 2004), blockade at 600 Hz frequency with less than 2 mA current is probably due to 
a muscle fatigue mechanism rather than nerve conduction blockade. The same 
neurostimulator was also implanted in paraplegic dogs for chronic experiments where it 
was demonstrated that the combination of low and high frequency stimuli resulted in 45 % 
reduction in EUS activity and that urine evacuation improved up to 91 % of the mean 
bladder capacity during the six months of chronic stimulation (Abdel-Gawad et al., 2001). 
The latest Polystim’s neurostimulation prototypes using that stimulation strategy were 
UroStim6 and UroStim7 presented in (Mounaim et al., 2006; Mounaim & Sawan, 2007) 
respectively. 
This chapter first describes a new sacral neurostimulation strategy to enhance micturition, 
based on nerve conduction blockade using high frequency stimulation as an alternative to 
rhizotomy. In order to test this strategy in chronic animal experiments, an implantable 
neurostimulation device is required. Thus, this chapter presents the design, test, prototyping 
and encapsulation of such neurostimulator (UroStim8) implementing the proposed 
stimulation strategy and using only commercially available discrete components. 
2. New stimulation strategy 
The proposed multi-site sacral neurostimulation strategy is illustrated in Fig. 1 and based on 
the following: High-frequency stimulation with an alternating waveform (such as sinusoidal 
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or rectangular) and optimum parameters, induces a blockade of the nerve (motor and/or 
sensory) activity, that may be complete (all axons) or partial (large diameter axons only). 
With a complete nerve blockade, the effect would be equivalent to that of rhizotomy while 
being controlled and totally reversible. With a partial blockade, selective stimulation can be 
achieved by blocking large axons only.  
 
S1
S2
Possible nerve stimulation sites, 
Low-frequency pulse waveform (e.g. 30Hz)
Right 
Sacral roots
Possible nerve conduction blockade sites,
High-frequency sinusoidal waveform (> 1kHz)
Spinal cord
Left 
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Selective blockade (large diameter axons only)
Stim. Stage 4Stim. Stage 3
Stim. Stage 2
Stim. Stage 1
Electrodes connected to the same stimulation stage
 
Fig. 1. Proposed multi-sites sacral neurostimulation strategy (dog model) 
In order to induce a contraction of the detrusor, a low-frequency (e.g. 30 Hz) pulse current 
stimulation is applied to S2 sacral nerve(s) (or S1 eventually), unilaterally or bilaterally. 
Adjusting the stimulation pulse amplitude and width, the degree of contraction can be 
modulated. In most cases, the EUS contracts as well. The stimulation-evoked EUS 
contraction may be explained by direct and/or reflex mechanisms due to efferent and/or 
afferent fibers activation respectively. Both types of EUS activation can be avoided by 
blocking axons innervating the EUS muscle with high-frequency (> 1 kHz) stimulation. A 
selective blockade can be applied distally (between the low-frequency stimulation site and 
the EUS) to inhibit direct EUS activation, while a complete blockade can be applied 
proximally (between the low-frequency stimulation site and the spinal cord), to inhibit 
reflex EUS activation. However, reflex EUS activation may involve sacral root(s) other than 
the one(s) stimulated by the low-frequency waveform. In such case, they should be blocked 
as well. Anatomically, the lower urinary tract innervations are the same from one animal to 
another but there is a functional variability. It is possible that one type of EUS activation 
mechanisms is dominant. For illustration purposes, Fig. 1 shows all possible blockade sites, 
but it is also possible that one blockade site prove to be sufficient. In case of incomplete SCI, 
conventional sacral nerve stimulation may lead to pain perception. Rhizotomy can be a way 
to abolish the stimulation-evoked pain but will probably not be considered at the cost of 
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losing important reflexes and sensations if still present. With the proposed stimulation 
strategy, a complete proximal high-frequency blockade of sensory activity during low-
frequency stimulation can inhibit pain sensation as well. Polystim Lab. recently presented 
preliminary results obtained with this strategy based on a dog model. Acute dog 
experiments were carried out and EUS blockade has been achieved in 8 animals after spinal 
cord transection (Mounaim et al. 2008; 2010). However, such experiments are not sufficient 
to validate the strategy especially that spinal shock generally lasts several weeks after SCI. 
Chronic experiments are mandatory in order to evaluate the long-term efficiency. This 
obviously requires a custom implantable neurostimulator that implements the proposed 
strategy, and will be capable of generating conventional stimulation waveforms as well as 
high-frequency sinusoids simultaneously over multiple channels. 
3. Discrete implantable neurostimulator 
3.1 Neurostimulator architecture 
The block diagram of Fig.2 illustrates the architecture of the implantable neurostimulator 
UroStim8 dedicated to the new stimulation strategy. The neurostimulator has been designed 
with commercially available off-the shelf components. The control unit is one of the latest 
generation of Field Programmable Gate Arrays (FPGA) that presents advantageous low-
power and small-scale features (Igloo, ACTEL). This FPGA also offers an In-Sytem 
Programming (ISP) feature that would allow (wired) subsequent code updates even after 
encapsulation of the neurostimulator. Such option was not possible with anti-fuse FPGAs 
used in previous prototypes (Ex, ACTEL) leading to the assembly of a new prototype for 
each new code to be tested. With near-field inductive coupling of spiral antennas, energy 
and data are wirelessly transmitted through the skin to the implanted stimulator using an 
external controller. The inductive coupling frequency used in previous prototypes was 20 
MHz, but to comply with the Industrial, Scientific and Medical (ISM) radio band, it is 
reduced to 13.56 MHz. This frequency is chosen taking into account the coupling 
attenuation through the skin tissues and the spiral inductors characteristics. The Power 
Recovery stage rectifies and filters the inductive carrier signal to provide different regulated 
power supplies to the stimulator. The Data Recovery stage demodulates the 600 kHz On-Off 
Keying (OOK) modulated carrier to provide Manchester-coded data to the FPGA. As soon 
as the inductive energy is present and the power supply sufficient, the FPGA starts 
Manchester decoding to extract data at 300 Kbps and a synchronized clock at 300 kHz. 
Transmission data frames are sent cyclically until the FPGA acknowledges that a valid one 
is received without errors using a low power and short-range 1 kbps RF uplink at 433 MHz. 
Depending on the received instruction and parameters, a specific mode is executed. This 
could be a stimulation mode where one or multiple Stimulation Stages outputs can be 
activated with chosen parameters, or a telemetry mode where impedance module and phase 
of each electrode-nerve interface (ENI) can be measured at a chosen frequency. Even though 
all stimulation stages are similar and can generate any waveform to a certain extent, 
Stimulation Stage 1 is dedicated to the low-frequency pulse waveform while Stages 2 to 4 
are dedicated to the high-frequency sinusoidal waveform. The stimulation frequency is 
common to Stages 2 to 4 but the stimulation current amplitude can be adjusted 
independently. The synchronized clock extracted from the Manchester-coded data was used 
as a time base for stimuli generation in previous neurostimulators. However, this clock 
suffers from time jitter due to inductive noise during data demodulation. Timing is very 
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important as for conventional biphasic stimulation for example, positive and negative 
phases must have the same duration so that total charge injection into the ENI is null. The 
oscillator in Fig. 2 is a low power component that brings a simple solution to this problem. 
Frequency of oscillation is adjusted with one resistance and an internal divider setting. The 
oscillator is activated for stimuli generation only and provides a stable clock of 300 kHz that 
can be eventually increased or decreased (hardware modification, not through the FPGA) 
depending on the available inductive power and the desired stimulation parameters. 
 
 
Fig. 2. Architecture of the UroStim8 neurostimulator dedicated to the new strategy 
3.2 Power and data recovery 
The neurostimulator front-end is responsible for power and data recovery as shown in Fig.3. 
Inductive energy transmitted by the external controller is recovered by the implanted 
stimulator using a parallel LC network resonating at the same frequency. Inductance L is a 
3-turn spiral antenna that is printed on a thin and flexible PCB with external diameter of less 
than 4 cm and a trace width of 1 mm to reduce the series resistance. Capacitance C is made 
of parallel combinations of ceramic NPO capacitors that offer high Q and high temperature 
stability. The capacitors are also specified for 100 V in order to maintain acceptable values at 
high voltages and high frequency. Ctune is a miniature variable capacitor that allows fine 
tuning of the resonant frequency to recover maximum energy with respect to the average 
power consumption of the implant. The voltage across the resonating LC network is an 
alternating signal that may exceed 60 V peak-to-peak in case of a high inductive coupling 
and a weak load. This signal is rectified with diodes (D1, D2) and filtered with the capacitor 
Cfilter which can be seen as the energy storage for the implant. Because of such high voltage, 
this capacitor has been chosen with a compromise between voltage specification (50 V), 
capacitance value (6.8 µF), and physical dimensions. When inductive coupling is suddenly 
interrupted, reverse currents may occur, leading to negative voltages at the input of the first 
regulator (Fig.3). Diode D4 protects the circuit from such situations. 
As shown in Fig.3, three linear regulators provide different power supply voltages to the 
neurostimulator. The first one is adjusted between 5 and 12 V for the supply of current 
sources and the analog supply of CMOS switches in the Stimuli Stages (Fig.4). This regulator  
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Fig. 3. Power and data recovery in UroStim8 
can tolerate high input voltages up to 80 V. The second regulator provides 3.3 V that is the 
main supply used by the FPGA Input/Outputs buffers, the DAC, the logic supply of CMOS 
switches in the Stimuli Stages, and the remaining components. This regulator provides a 
Power-OK (POK) signal that indicates to the FPGA that the 3.3V supply is available and 
well regulated. No stimulation will be started unless the POK signal is high. Finally, the 
third supply of 1.5 V is used by the FPGA core only to reduce its power consumption.  
To protect the system from a high induced voltage, power recovery circuits use voltage 
clipping, Zener diodes or shunt regulators (Schneider, 2001; Ba et al., 2002; Ba, 2004; Yunlei 
& Jin, 2005; Balachandran & Barnett, 2006). In previous neurostimulators, a shunt regulator 
was adjusted to be able to provide the required voltage supply in the worst case that is 
maximum stimulator current consumption and minimum available inductive energy. 
However, except in this case, it is not an efficient solution because the shunt regulator 
simply short-cuts the excess current. With the high input voltage of the first regulator, there 
is no need for voltage limiting, and the excess of inductive energy translates to voltage 
instead of current. Voltage is indirectly limited by the maximum available inductive energy 
and the minimum stimulator current consumption. Compared to the zener shunt regulator, 
it is a more efficient solution that also allows recovering high voltage supply for stimulation 
without using step-up DC/DC converters. For data recovery, the OOK demodulator is a 
simple envelope detector which is implemented as an amplification of small variations 
across diode D3 that is stacked in series between the rectifier diodes (D1, D2) and the 
common ground. These variations are due to the carrier modulation and are amplified with 
the NPN transistor T1 in a common-base configuration. A pull-up resistor R1 limits the 
current when the demodulated data signal is low but also limits its rising time. The design 
simplicity of this demodulator is the reason behind the choice of such modulation scheme 
for data transmission. However, the OOK modulation turns-off the coupling carrier with a 
duty cycle of around 50 % for each Manchester-coded bit. Consequently, inductive energy is 
wasted because of the simultaneous data transfer. Now that an oscillator provides a stable 
clock, the recovered clock is not needed anymore for stimuli generation. Thus, as soon as the 
FPGA acknowledges to the external controller a valid transmission, the downlink data 
transfer is stopped while keeping the inductive coupling. That way, more inductive energy 
is available for stimulation or telemetry. 
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3.3 Stimulation stages 
UroStim8 neurostimulator has 4 stimulation stages. As presented in Fig.4, Stage 1 is 
dedicated to the low-frequency pulse stimulation, offers 4 bipolar outputs, and includes an 
8-bit Digital to Analog Converter (DAC), an Operational Amplifier (OpAmp) used as a 
current source, as well as CMOS analog switches for biphasic stimulation and outputs 
multiplexing.  
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Fig. 4. Stimulation stages in UroStim8 
The four outputs of Stage 1 share the same frequency and can be activated individually or in 
any combination. Even though meant for simultaneous stimulation, the four low-frequency 
pulse outputs are sequentially activated with a small delay to avoid cumulative power 
consumption load peaks. Thus, pulse amplitude can be programmed independently which 
is important because the impedance of the cuff-electrodes may be different. Before each 
stimulation pulse, the FPGA sends the amplitude code to the DAC that provides a 
proportional voltage VDAC between 0 and a reference voltage of 1.2 V. This voltage is then 
converted into current by the OpAmp and resistance Res1 that operates as a current source. 
Constant current is injected into the nerve via CMOS analog switches that enables reversing 
the current for biphasic stimulation. The stimulation current is equal to Istim=VDAC1 /Res1, 
as long as the OpAmp is not saturated. Resistance Res1 has been chosen equal to 600 Ω to 
provide a maximum current of 2 mA (1.2 V/600 Ω). For an ENI impedance of 1 kΩ, a 
voltage supply of 3.3 V would have been sufficient for the OpAmp. However, previous 
chronic animal experiments proved that the ENI impedance may become higher than 4 kΩ 
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leading to lower stimulation currents because of the OpAmp saturation. Hence, its voltage 
supply can be increased up to 12 V so that a current of 2 mA could be injected into an ENI 
impedance up to 5.4 kΩ. Stimulation Stages 2 to 4 share the same DAC that will generate the 
sinusoidal waveform required for nerve conduction blockade. They offer 8 bipolar outputs 
that are grouped according to the stimulation strategy (Fig.1). For the three groups of 
outputs, the blockade amplitude can be adjusted independently through digital 
potentiometers Res2 to 4. The stimulation stages are controlled by the FPGA similarly but 
separately. Signals UP and DOWN sets the current direction with an H-Bridge that is made 
of four switches mounted as a mixer. Signal ZERO controls a fifth switch that shortcuts the 
OpAmp output with its negative input before activating one of the UP or DOWN signals. 
That way, before and after each pulse, the same voltage is applied on both electrodes (of 
each bipolar output) before releasing the ZERO switch (Mounaim & Sawan, 2007). The 
output CMOS analog switches are critical elements. If they must transmit currents under 
voltages as high as 12 V, they still need to be controlled by 3.3 V signals directly from the 
FPGA. Thus, they have been chosen with dual power supplies: a logic supply of 3.3 V and 
an analog supply up to 12 V. 
3.4 Telemetry 
The goal of the implemented telemetry is to verify the capacity of the implant to stimulate 
each connected nerve. Thus, it is important to monitor the load impedance presented by 
each ENI as it must not be too high for the desired stimulation current (Sawan et al., 2007, 
2008a). 
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Fig. 5. Telemetry in UroStim8 
The neurostimulator has a total of 12 bipolar outputs. Making use of the demultiplexers 
already present in the stimulation stages, monitoring can be done at the current source 
OpAmp output of each stage by activating one single bipolar output at a time. As shown in 
Fig.5, the four differential OpAmp outputs voltages are multiplexed, differentially 
measured with an instrumentation amplifier and then sampled with an Analog to Digital 
Converter (ADC) before being sent to the FPGA. The stimulus used for AC impedance 
measurement is a sinusoidal waveform that each stimulation stage is capable of generating. 
After a programmable number of cycles, the maximum amplitude and zero-crossing time of 
the voltage difference across the ENI, are used with the programmed stimulation 
parameters to estimate the impedance module and phase respectively. Once these 
measurements are ready, they are sent to the external controller thanks to a miniature 
transmission module. It is an RF emitter oscillating at 433 MHz and OOK modulated at 1 
kHz. The transmission range can be adjusted with a digital potentiometer (Res5) that limits 
the driving current.  
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5. Results 
The complete UroStim8 neurostimulator prototype has been assembled on a large 
breadboard for design and tests. Table 1 presents the achieved stimulation parameters and 
Fig. 6 presents different oscilloscope screen captures. Fig. 6a shows the low-frequency pulse 
stimulation waveform generated by Stimulation Stage 1. Single-end outputs are probed by 
oscilloscope channels Ch1 and Ch2 respectively. The differential output (Ch1-Ch2) is shown 
by the Math curve (M). Control signals ZERO1 and UP1 (according to Fig. 4) are probed by 
channels Ch3 and Ch4 respectively. The waveform is not a conventional biphasic one but 
rather an alternating monophasic waveform as proposed in (Mounaim & Sawan, 2007). Fig. 
6b shows the Stimulation Stage 1 OpAmp's output Vout1 (Ch1) when all four bipolar 
outputs are activated. Ch2 to 4 probe three of them (single-ends only). Stimulation on the 
four outputs is not "truly" simultaneous but rather alternated with a small delay between 
pulses. This has the advantage of avoiding large current consumption peaks but also 
allowing different pulse amplitudes for each output. Fig. 6c and 6d show the high-frequency 
sinusoidal waveform at the minimum and maximum achieved frequencies respectively. For 
both figures, single-end outputs are probed by Ch1 and Ch2, control signals UP and DOWN 
(according to Fig. 4) by channels Ch3 and Ch4 respectively, while the differential output is 
shown by the Math curve (M). 
 
Waveform Pulse Sinusoid 
Parameters Amp. Width Frequency Frequency Amp. 
Max 2 mA 217 µs 
8.9 kHz (with min 
width) 
1 kHz (with max width) 
8.6 kHz 2 mA 
Min 0 3.39 µs 18 Hz 1 kHz 0 
Resolution 8 µA Time resolution = 3.39 µs (clock = 295 kHz) 8 µA 
Table 1. UroStim8 measured stimulation parameters 
A normalized half-period of the waveform is stored as a map table of 1024 amplitude 
samples. To change the frequency of stimulation, the map table is read with a memory 
address step as it is scanned with the 300 kHz clock. The general equation determining the 
digitally programmed sinusoidal frequency is given by equation (1). 
 
1
2 1024
300 5
7
Frequency kHz
F
−∗⎛ ⎞= ∗ +⎜ ⎟+⎝ ⎠  (1) 
where F is the decimal equivalent of a programmable 6-bit binary code. As the frequency is 
increased, the resulting total number of amplitude steps is reduced from more than 256 
(=2*1024/8) to less than 32 (=2*1024/64). Any other stimulation waveform and/or mapping 
strategy can be easily implemented by reprogramming the FPGA. Table 2 presents the 
measured system total current consumption at different conditions. With all stimulation 
stages and all their outputs activated, total system current consumption is 4.54 mA (rms) at 
30 Hz pulse (2 mA, 217 µs) and 1 kHz sinusoidal frequencies. For Stimulation Stages 2-4, 1 
mA current is distributed over outputs of each stage. Thus, stimulation parameters must be 
adjusted taking into account the available inductive power energy. The FPGA core current 
consumption in this prototype is less than 100 µA. 
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Stim. Stage 1 
single-end outputs
Stim. Stage 1 
OpAmp output 
(Vout1)
 
(a) (b) 
UP
DOWN
single-end 
outputs 
differential output (Ch1 – Ch2)
  
(c) (d) 
Fig. 6. Oscilloscope captures showing (a) alternating monophasic stimulation waveform and 
control signals, (b) Stimulation Stage 1 OpAmp output and three single-ends outputs, and 
sinusoidal waveform at (c) 1 kHz and (d) 8.6 kHz frequencies 
 
Conditions Current consumption 
Stimulation Stage 1 Stimulation Stages 2-4 mA (rms) 
OFF OFF 1.83 
30 Hz OFF 2.12 
1 kHz OFF 4.59 
30 Hz 1 kHz 4.54 
30 Hz 8.6 kHz 5.33 
1 kHz 8.6 kHz 7.80 
Table 2. UroStim8 measured system total current consumption (rms) with following 
stimulation conditions: Stage 1 (2 mA, 217 µs); Stages 2-4 (1 mA each, current is distributed 
over outputs of each stage) 
UroStim8 neurostimulator’s printed circuit board have been designed, fabricated and 
assembled as shown in Fig. 7. UroStim8's PCB is 38 mm diameter and can host a FPGA in 
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12x12 Fine Pitch Ball Grid Array (FBGA) of 13x13 mm dimensions and 1 mm pitch. Because 
of the relatively large number of discrete components and the limited space, the design of 
such PCB is challenging. It required eight PCB layers and numerous blind vias for a 
complete routing of the system. For chronic animal implantation, the prototype will be 
encapsulated in two layers of different materials. The first layer is a rigid epoxy that protects 
the implant from infiltration of fluids and offers a reliable isolation for the electronic 
components. The second layer is a biocompatible silicone that offers a soft contact for 
corporal tissues. Encapsulation is done using custom made Teflon or aluminum moulds. 
Fig. 8 shows the targeted encapsulation dimensions for the neurostimulator. The 
encapsulated UroStim8 will be thinner than previous prototypes that had embedded 
batteries (10 mm compared to 16 mm). 
 
Top view Bottom view Inductor 
   
Fig. 7. UroStim8 printed circuit board 
 
40
 m
m
10
 m
m
59 mm
 
UroStim8 
Fig. 8. UroStim8 encapsulation dimensions 
6. Conclusion 
This chapter presented a new sacral neurostimulation strategy to enhance micturition in 
spinal cord injured patients. In order to carry-on chronic animal experiments, a discrete 
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implantable neurostimulator has been designed implementing the proposed stimulation 
strategy and using commercially available discrete components. Measurements and 
prototyping results were presented. The discrete prototype is capable of generating a low 
frequency pulse waveform as low as 18 Hz with a simultaneous high frequency alternating 
waveform as high as 8.6 kHz, and that over different and multiple channels. With all 
stimulation stages and all their outputs activated, total system current consumption is 
around 4.5 mA (rms) at 30 Hz pulse (2 mA, 217 µs) and 1 kHz sinusoidal frequencies. In the 
same conditions, using a sinusoidal stimulation at the highest frequency of 8.6 kHz, 
increases current consumption up to 7.8 mA. With 50 mW of available inductive power for 
example and 4.5 mA current consumption, the high voltage regulator can be set to 10 V 
allowing 2 mA stimulation of 4.4 kΩ electrode-nerve impedance. However, with 7.8mA 
current consumption, the high voltage regulator will have to be set to 6 V reducing the 
maximum possible stimulation current to 1 mA for a 4.4 kΩ electrode-nerve impedance. 
Thus, the effective number of activated outputs and the maximum achievable stimulation 
parameters are limited by the available energy provided by the inductive link and the 
impedance of the electrode-nerve interfaces. Future developments will include chronic 
animal experiments after full characterization of the encapsulated and implanted 
neurostimulation prototype, taking into account the resulting inductive link efficiency. 
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